Medeon Biodesign, Inc. (TPEX:6499)
Taiwan · Delayed Price · Currency is TWD 95.00
+2.30 (2.48%)
At close: Feb 11, 2026
Medeon Biodesign Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 381.9 | 292.81 | 196.26 | 298.32 | 68.96 | 123.06 | |
Revenue Growth (YoY) | 40.96% | 49.19% | -34.21% | 332.61% | -43.96% | -72.88% |
Cost of Revenue | 330.77 | 209.39 | 181.89 | 111.51 | 40.33 | 76.75 |
Gross Profit | 51.14 | 83.41 | 14.38 | 186.81 | 28.63 | 46.3 |
Selling, General & Admin | 186.37 | 203.75 | 185.91 | 153.03 | 108.35 | 98.5 |
Research & Development | 649.99 | 751.87 | 667.46 | 521.62 | 415.87 | 289.94 |
Operating Expenses | 845.48 | 969.03 | 853.94 | 674.65 | 524.22 | 388.05 |
Operating Income | -794.34 | -885.61 | -839.57 | -487.84 | -495.59 | -341.75 |
Interest Expense | -4.14 | -5.56 | -6.64 | -5.21 | -1.03 | -1.39 |
Interest & Investment Income | 9.35 | 20.17 | 19.94 | 10.29 | 6.12 | 9.61 |
Earnings From Equity Investments | - | - | 13.54 | 47.69 | 19.66 | - |
Currency Exchange Gain (Loss) | -1.82 | 14.43 | -6.19 | 15.35 | - | - |
Other Non Operating Income (Expenses) | 0.15 | 0.2 | 0.39 | 0.34 | -43.07 | -8.59 |
EBT Excluding Unusual Items | -790.8 | -856.37 | -818.53 | -419.38 | -513.91 | -342.12 |
Gain (Loss) on Sale of Investments | -0.16 | -2.28 | -399.15 | -19.73 | - | - |
Gain (Loss) on Sale of Assets | - | - | -13.01 | - | - | - |
Pretax Income | -790.96 | -858.64 | -1,231 | -439.12 | -513.91 | -342.12 |
Income Tax Expense | -0.42 | 11.88 | 39.29 | 57.79 | 72.46 | 5.28 |
Earnings From Continuing Operations | -790.54 | -870.52 | -1,270 | -496.9 | -586.36 | -347.4 |
Earnings From Discontinued Operations | - | - | - | - | 2,618 | 177.81 |
Net Income to Company | -790.54 | -870.52 | -1,270 | -496.9 | 2,031 | -169.59 |
Minority Interest in Earnings | 50.75 | 65.01 | 65.36 | 63.14 | 46.75 | -23.15 |
Net Income | -739.79 | -805.51 | -1,205 | -433.76 | 2,078 | -192.74 |
Net Income to Common | -739.79 | -805.51 | -1,205 | -433.76 | 2,078 | -192.74 |
Shares Outstanding (Basic) | 92 | 92 | 92 | 92 | 92 | 92 |
Shares Outstanding (Diluted) | 92 | 92 | 92 | 92 | 92 | 92 |
Shares Change (YoY) | 0.07% | 0.11% | 0.02% | -0.07% | 0.48% | 0.05% |
EPS (Basic) | -8.03 | -8.74 | -13.09 | -4.71 | 22.65 | -2.10 |
EPS (Diluted) | -8.03 | -8.74 | -13.09 | -4.71 | 22.65 | -2.10 |
Free Cash Flow | -676.62 | -906.97 | -810.36 | -601.91 | -301.69 | -171.44 |
Free Cash Flow Per Share | -7.34 | -9.84 | -8.80 | -6.54 | -3.28 | -1.87 |
Dividend Per Share | - | - | - | 0.476 | 0.794 | - |
Dividend Growth | - | - | - | -40.00% | - | - |
Gross Margin | 13.39% | 28.49% | 7.32% | 62.62% | 41.52% | 37.63% |
Operating Margin | -208.00% | -302.45% | -427.78% | -163.53% | -718.69% | -277.72% |
Profit Margin | -193.71% | -275.10% | -613.78% | -145.40% | 3013.75% | -156.62% |
Free Cash Flow Margin | -177.17% | -309.75% | -412.90% | -201.77% | -437.51% | -139.31% |
EBITDA | -738.16 | -839.21 | -797.3 | -459.64 | -463.09 | -284.45 |
EBITDA Margin | -193.28% | -286.61% | - | -154.08% | - | -231.16% |
D&A For EBITDA | 56.18 | 46.4 | 42.26 | 28.2 | 32.5 | 57.3 |
EBIT | -794.34 | -885.61 | -839.57 | -487.84 | -495.59 | -341.75 |
EBIT Margin | -208.00% | - | - | -163.53% | - | -277.72% |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.